

Instructions for Authors 2016

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide prompt (print and online) publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC – IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to IN VIVO 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2016 International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Specific information and additional instructions for Authors

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

5. Authors should pay attention to the following points when writing an article for IN VIVO:
- The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to IN VIVO may be rejected without review if:
- they do not fall within the journal's policy.
 - they do not follow the instructions to authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to IV.
 - plagiarism is detected by plagiarism screening services.
- (Rejection rate (2015): 58%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org.
11. Reprints of published articles are usually delivered to the corresponding Author, within 1 month after publication.
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).
Copyright © 2016 IAR (J.G. Delinasios)

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN (print): 0250-7005; ISSN (online): 1791-7530

- ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.
- ANTICANCER RESEARCH is published monthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press. The IIAR is a member of UICC.
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

● Selection of Recent Articles

Using Epigenetic Therapy to Overcome Chemotherapy Resistance. J. STRAUSS, W.D. FIGG (*Bethesda, MD, USA*)

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. N. FAZIO, R. BUZZONI, E. BAUDIN, L. ANTONUZZO, R.A. HUBNER, H. LAHNER, W.W. DE HERDER, M. RADERER, A. TEULÉ J. CAPDEVILA, S.K. LIBUTTI, M.H. KULKE, M. SHAH, D. DEY, S. TURRI, P. AIMONE, C. MASSACESI, C. VERSLYPE (*Milan; Florence, Italy; Villejuif; Paris, France; Manchester, UK; Essen, Germany; Rotterdam, the Netherlands; Vienna, Austria; Barcelona, Spain; New York, NY; Boston, MA; Columbus, OH, USA; Hyderabad, India; Basel, Switzerland; Leuven, Belgium*)

Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. D. KILARI, K.A. ICZKOWSKI, C. PANDYA, A.J. ROBIN, E.M. MESSING, E. GUANCIAL, E.S. KIM (*Milwaukee, WI; Rochester, NY, USA*)

Radioembolization Versus Chemoembolization (DEBDOX) for the Treatment of Unresectable Hepatocellular Carcinoma: A Propensity Matched Study. O. AKINWANDE, P. PHILIPS, C. SCOGGINS, R.C.G. MARTIN (*Baltimore, MD; Louisville, KY, USA*)

Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer. M. WINTHER, J. ALSNER, B.S. SØRENSEN, C.F. WITTRUP, T. TRAMM, L. BAEKSGAARD, K. HOFLAND, E. HOLTVED, M. NORDSMARK (*Aarhus; Copenhagen; Odense, Denmark*)

Human Papillomavirus as Diagnostic and Prognostic Tool in Cancer of Unknown Primary in the Head and Neck Region. L. SIVARS, E. TANI, A. NÄSMAN, T. RAMQVIST, E. MUNCK-WIKLAND, T. DALIANIS (*Stockholm, Sweden*)

Restoring Natural Killer Cell Cytotoxicity after Hyperthermia Alone or Combined with Radiotherapy. T. HIETANEN, M. KAPANEN, P.-L. KELLOKUMPU-LEHTINEN (*Tampere, Finland*)

Split-Course Accelerated Hypofractionated Radiotherapy (SCAHT): A Safe and Effective Option for Head and Neck Cancer in the Elderly or Infirm. T.J. BLEDSOE, A.R. NOBLE, C.A. REDDY, B.B. BURKEY, J.F. GRESKOVICH, T. NWIZU, D.J. ADELSTEIN, J.P. SAXTON, S.A. KOYFMAN (*New Haven, CT; Cleveland, OH, USA*)

Demonstration of Calreticulin Expression in Hamster Pancreas Adenocarcinoma with the Use of Fluorescent Gold Quantum-Dots. E. GIORGAKIS, B. RAMESH, A. KAMALI-DASHTARZHENEH, G. KITO FUSAI, C. IMBER, D. TSIRONIS, M. LOIZIDOU (*London, UK*)

Potential Dual Role of Activating Transcription Factor 3 in Colorectal Cancer. X. JIANG, K.-J. KIM, T. HA, S.-H. LEE (*College Park, MD, USA*)

Intestinal Tumour Development in C57BL/6J-Apc^{min/+} Mice Expressing Human Sulphotransferases 1A1 And 1A2 after Oral Exposure to 2,5-Dimethylfuran. A. HORTOMO HØIEA, C. SVENDSENA, T. RASMUSSENA, J. ALEXANDERB, T. HUSØY (*Oslo, Norway*)

Decreased Expression of Tumor Suppressor Gene LKB1 Correlates with Poor Prognosis in Human Gastric Cancer. J. SUN, B. LING, X. XU, R. MA, G. LI, X. CAO, W. LING, Z. YANG, R.M. HOFFMAN, J. LU (*Nanjing, Jiangsu, PR China; San Diego, CA, USA*)

Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue. M. VORA, J. ANSARI, R.M. SHANTI, D. VEILLON, J. COTELINGAM, D. COPPOLA, R.E. SHACKELFORD (*Shreveport, LA; Tampa, FL, USA*)

Effect of Postmastectomy Radiation on Survival of AJCC pN2/N3 Breast Cancer Patients. Z. SHI, P. PEDDI, G. BURTON, G. MILLS, R. SHI (*New York, NY; Shreveport, LA, USA*)

FREE SPECIMEN COPIES OF ANTICANCER RESEARCH ARE AVAILABLE ON REQUEST

CANCER GENOMICS & PROTEOMICS

International Online **Open Access** Journal

www.cgp.iiarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online with **Stanford University HighWire Press**. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

A Selection of Recent Articles

Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma. X. LAI, S. CHEN (*Indianapolis, IN, USA*)

A Low-density Antigen Array for Detection of Disease-associated Autoantibodies in Human Plasma. R.I. SOMIARI, R. SUTPHEN, K. RENGANATHAN, S. RUSSELL, E. PASTWA, S.A. SOMIARI (*Johnstown; Windber, PA; Tampa, FL, USA*)

WNT/ β -catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma. T. DENYSENKO, L. ANNO-VAZZI, P. CASSONI, A. MELCARNE, M. MELLAI, D. SCHIFFER (*Vercelli; Turin, Italy*)

Identification of Endogenous Controls for Use in miRNA Quantification in Human Cancer Cell Lines. M.K. DAS, R. ANDREASSEN, T.B. HAUGEN, K. FURU (*Oslo, Norway*)

Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. D.J. BIRNBAUM, F. BERTUCCI, P. FINETTI, J. ADELAÏDE, M. GIOVANNINI, O. TURRINI, J.R. DELPERO, J.L. RAOUL, M. CHAFFANET, V. MOUTARDIER, D. BIRNBAUM, E. MAMESSIER (*Marseille, France*)

Doxorubicin Affects Expression of Proteins of Neuronal Pathways in MCF-7 Breast Cancer Cells. M. PETROVIC, C. SIMILLION, P. KRUZLIK, J. SABO, M. HELLER (*Kosice, Slovak Republic; Bern, Switzerland; Brno, Czech Republic*)

Molecular Mechanisms of Bone Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (*Penzberg, Germany*)

Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling. E. KJELDSEN (*Aarhus, Denmark*)

MTA1 Is Up-regulated in Colorectal Cancer and Is Inversely Correlated with Lymphatic Metastasis. J. LI, L. YE, P.-H. SUN, L. SATHERLEY, R. HARGEST, Z. ZHANG, W.G. JIANG (*Cardiff, UK; Beijing, PR China*)

Ensuring Sample Quality for Biomarker Discovery Studies – Use of ICT Tools to Trace Biosample Life-cycle. S. RIONDINO, P. FERRONI, A. SPILA, J. ALESSANDRONI, R. D'ALESSANDRO, V. FORMICA, D. DELLA-MORTE, R. PALMIROTTA, U. NANNI, M. ROSELLI, F. GUADAGNI (*Rome, Italy*)

Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. S. SUGIE, S. MUKAI, K. YAMASAKI, T. KAMIBEPPU, H. TSUKINO, T. KAMOTO (*Miyazaki, Japan*)

Delayed 5-Fluorouracil Toxicity with Uridine Triacetate in Patients with Dihydropyrimidine Dehydrogenase Deficiency. M.W. SAIF, R.B. DIASIO (*Boston, MA; Rochester, MN, USA*)

Clinical Studies

Management of Very Early-onset Fetal Growth Restriction: Results from 92 Consecutive Cases. F. HOELLEN, A. BECKMANN, C. BANZ-JANSEN, J. WEICHERT, A. RODY, M.K. BOHLMANN (<i>Lübeck; Mannheim, Germany</i>)	123
Prehospital CPAP Therapy by Emergency Physicians in Patients with Acute Respiratory Failure due to Acute Cardiogenic Pulmonary Edema or Acutely Exacerbated COPD. T. LUIZ, M. KUMPCH, J. GRÜTTNER, C. MADLER, T. VIERGUTZ (<i>Kaiserslautern; Mannheim, Germany</i>)	133
Axillary Lymph Node Metastases of Melanoma: Management of Third-level Nodes. D. GENTILE, P. COVARELLI, F. PICCIOTTO, V. CALIENDO, L. STINGENI, R. DEL SORDO, A. RULLI (<i>Perugia; Turin, Italy</i>)	141
Etiological Observations in Seven Patients with Pancreatic Neuroendocrine Tumors (PNETs). J. LANDIN, W. WEBER (<i>Basel, Switzerland</i>)	147
The Effect of Reactive Oxygen Species on Embryo Quality in IVF. C. SIRISTATIDIS, P. VOGIATZI, C. VAROUNIS, M. ASKOXYLAKI, C. CHRELIAS, N. PAPANTONIOU (<i>Athens, Greece</i>)	149
Stereotactic Body Radiotherapy Provides Excellent Long-Term Local Control of Very Few Lung Metastases. S. JANSSEN, L. KÄSMANN, V. RUDAT, D. RADES (<i>Lübeck; Hannover, Germany; Al Khobar, Kingdom of Saudi Arabia</i>)	155
Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer. Y.-C. LU, F. OU-YANG, C.-M. HSIEH, K.-J. CHANG, D.-R. CHEN, C.-W. TU, H.-C. WANG, M.-F. HOU (<i>Chiayi; Tainan; Kaohsiung; Taipei; Taichung; Changhua, Taiwan, ROC</i>)	159